Pernix Theraptcs Cmn (PTX) 0.59 $PTX
Pernix Therapeutics Announces Reorganization of Senior Management Team
GlobeNewswire - Tue Jul 26, 4:40PM CDT
John Sedor Appointed CEO on a Permanent Basis
PTX: 0.59 (+0.02)
Pernix Therapeutics Announces Restructuring of Sales Force and Operations
GlobeNewswire - Thu Jul 07, 5:30AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ
TX) ("Pernix" or the "Company"
, a specialty pharmaceutical company, today announced an initiative intended to optimize the Company's resources and improve the effectiveness of its sales force. As part of this effort, Pernix has reduced its total full-time work force by approximately 23 percent.
PTX: 0.59 (+0.02)
Pernix Therapeutics Announces Positive Phase IV Results of Silenor(R) vs. Zolpidem Head-to-Head Arousability Study
GlobeNewswire - Thu Jun 16, 7:00AM CDT
Data demonstrated that Pernix Therapeutics' Silenor 6 mg was superior to zolpidem 10 mg on all measures evaluated.
PTX: 0.59 (+0.02)
Pernix Therapeutics Announces the Issuance of Three New Orange Book Patents for Zohydro(R) ER with BeadTek(TM)
GlobeNewswire - Wed May 25, 7:08AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQTX), a specialty pharmaceutical company, today announced that the United States Patent and Trademark Office has issued U.S. Patent Numbers 9,339,499 ('499 patent), 9,326,982 ('982 patent), and 9,333,201 ('201 patent), covering important safety information related to dosing patients with Zohydro ER with BeadTek. These patents, in addition to the 9,265,760 patent ('760 patent) which issued February 23, 2016, are broadly directed to a method of dosing patients with hepatic impairment with hydrocodone where no adjustment in start dose is needed for patients with mild or moderate hepatic impairment. The '760, '499, '982 and '201 patents expire July 25, 2033.
PTX: 0.59 (+0.02)
Pernix Therapeutics Announces CEO Transition
GlobeNewswire - Wed May 11, 7:00AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQTX), a specialty pharmaceutical company, today announced that Doug Drysdale, after discussions with the Company's Board of Directors, has agreed to step down as Chairman of the Board, Chief Executive Officer and President, and has resigned as a member of the Board of Directors, effective May 9, 2016. John Sedor, a current Director of Pernix Therapeutics, has been appointed Chairman of the Board and Interim Chief Executive Officer of the Company while the Board of Directors searches for a permanent CEO. The Board currently intends that Mr. Sedor will remain as Chairman of the Board when a new CEO is appointed.
PTX: 0.59 (+0.02)
Pernix Therapeutics Overcomes Challenge to Treximet(R) '183 Patent
GlobeNewswire - Mon May 09, 7:00AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQTX), a specialty pharmaceutical company, today announced that on May 6, 2016, the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) denied a petition for inter partes review (IPR) filed by Graybar Pharmaceuticals, LLC (now Gray Square Pharmaceuticals, LLC) against Pozen, Inc. This petition, which was filed on November 12, 2015, sought review of certain claims of U.S. Patent No. 7,332,183 ('183 patent), which expires 2026. The '183 patent is licensed by Pernix and is one of several FDA Orange Book listed patents covering Treximet(R), manufactured and sold by Pernix Therapeutics, (sumatriptan/naproxen sodium), a prescription medication for acute migraine attacks, with or without aura.
PTX: 0.59 (+0.02), POZN: 5.94 (-0.43)
Pernix Therapeutics reports 1Q loss
Automated Insights - Thu May 05, 8:19AM CDT
MORRISTOWN, N.J. (AP) _ Pernix Therapeutics Holdings Inc. (PTX) on Thursday reported a loss of $25.9 million in its first quarter.
PTX: 0.59 (+0.02)
Pernix Therapeutics Reports First Quarter 2016 Financial Results and Business Update
GlobeNewswire - Thu May 05, 7:01AM CDT
Pernix Prescriptions Direct Achieves Increased Penetration
PTX: 0.59 (+0.02)
Pernix Therapeutics to Report First Quarter 2016 Financial Results on Thursday, May 5, 2016
GlobeNewswire - Thu Apr 28, 7:30AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQTX), a specialty pharmaceutical company, announced today that it will release financial results for the first quarter ended March 31, 2016, before the market opens on Thursday, May 5, 2016. Doug Drysdale, Chairman and Chief Executive Officer, and Sanjay Patel, Chief Financial Officer, will host a conference call to discuss the results, as follows.
PTX: 0.59 (+0.02)
Pernix Therapeutics to Present at Needham & Company's 15th Annual Healthcare Conference
GlobeNewswire - Tue Apr 05, 3:01PM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQTX), a specialty pharmaceutical company, announced today that Doug Drysdale, Chairman and Chief Executive Officer, and Sanjay Patel, Chief Financial Officer, will present at Needham & Company's 15th Annual Healthcare Conference, as follows.
PTX: 0.59 (+0.02)
Pernix Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Business Update
GlobeNewswire - Thu Mar 10, 7:00AM CST
Full Year 2015 Revenue Increases 44% Year-Over-Year to $176 Million
PTX: 0.59 (+0.02)
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launch Investigation of Pernix Therapeutics Holdings, Inc. for Possible Breaches of Fiduciary Duty
PR Newswire - Thu Jan 14, 11:15AM CST
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX) in connection with possible breaches of fiduciary duty.
PTX: 0.59 (+0.02)
Zogenix, Inc Gained 29% in 2015 -- Here's Why
Brian Feroldi, The Motley Fool - Motley Fool - Thu Jan 14, 10:59AM CST
What: 2015 was a great year to be a Zogenix shareholder. The clinical-stage biopharmaceutical company's stock soared more than 29% higher during the year, according to data from S&P Capital IQ . So what: The year was filled with...
PTX: 0.59 (+0.02), ZGNX: 9.13 (+0.05)
The Zacks Analyst Blog Highlights: Amphastar Pharmaceuticals, Mylan, Pernix Therapeutics Holdings, Eli Lilly and Novo Nordisk
Zacks Equity Research - Zacks Investment Research - Wed Nov 25, 8:30AM CST
The Zacks Analyst Blog Highlights: Amphastar Pharmaceuticals, Mylan, Pernix Therapeutics Holdings, Eli Lilly and Novo Nordisk
NVO: 56.97 (+0.43), PTX: 0.59 (+0.02), MYL: 46.79 (+0.07), LLY: 82.89 (-0.04), AMPH: 16.18 (-0.09)
Forget Allergan & Pfizer, Buy These Drug Stocks Instead
Arpita Dutt - Zacks Investment Research - Tue Nov 24, 11:09AM CST
Let's take a look at some drug stocks with an attractive Zacks Rank and positive estimate revisions.
AGN: 252.95 (-2.61), NVO: 56.97 (+0.43), PTX: 0.59 (+0.02), PFE: 36.89 (+0.22), MYL: 46.79 (+0.07), LLY: 82.89 (-0.04), AMPH: 16.18 (-0.09)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of Pernix Therapeutics Holdings, Inc. - PTX
ACCESSWIRE - Mon Nov 16, 3:30PM CST
NEW YORK, NY / ACCESSWIRE / November 16, 2015 / Levi & Korsinsky announces it has commenced an investigation of Pernix Therapeutics Holdings, Inc. (NasdaqGM: PTX) concerning possible breaches of fiduciary duty by its Board of Directors. To obtain additional information, GO TO:
PTX: 0.59 (+0.02)
Pernix Therapeutics to Present at Stifel 2015 Healthcare Conference
GlobeNewswire - Fri Nov 13, 6:00AM CST
Pernix Therapeutics Holdings, Inc. (NASDAQTX), a specialty pharmaceutical company, announced today that Doug Drysdale, Chairman, President and Chief Executive Officer, and Sanjay Patel, Chief Financial Officer, will present at the Stifel 2015 Healthcare Conference as follows:
PTX: 0.59 (+0.02)
Pernix Therapeutics Holdings, Inc. Announces Positive Interim Results From a Phase IV Study to Assess and Compare the Effects of Silenor 6 mg and zolpidem 10 mg on Balance, Cognitive Performance, and Arousability
GlobeNewswire - Thu Nov 12, 10:15AM CST
Pernix Therapeutics Holdings, Inc. (NASDAQTX), a specialty pharmaceutical company, today announced positive interim results from a Phase IV Study assessing the effects of a nighttime administration of Silenor 6 mg, zolpidem 10 mg, and placebo on arousability, gait/balance, and cognitive performance in healthy volunteers. The study assessed the effects of a single dose of Silenor 6 mg compared with matching placebo and a single dose of zolpidem 10 mg compared to its matching placebo at the respective Tmax (amount of drug present at the maximum serum concentration) in normal healthy adult male volunteers (n=39). The interim results of this head-to-head comparison demonstrate that Silenor 6 mg is statistically significantly superior to zolpidem 10 mg on all measures analyzed. The results also indicate that subjects taking Silenor 6 mg did not have impairment on any of these measures and were comparable to placebo. Further, Silenor 6 mg and both placebo groups were superior to zolpidem on all measures, indicating that zolpidem subjects had significant difficulty waking up, difficulty in their ability to walk, difficulty with balance, and experienced memory impairment.
PTX: 0.59 (+0.02)
Pernix Therapeutics Announces Reorganization of Senior Management Team
GlobeNewswire - Tue Jul 26, 4:40PM CDT
John Sedor Appointed CEO on a Permanent Basis
PTX: 0.59 (+0.02)
Pernix Therapeutics Announces Restructuring of Sales Force and Operations
GlobeNewswire - Thu Jul 07, 5:30AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ
TX) ("Pernix" or the "Company", a specialty pharmaceutical company, today announced an initiative intended to optimize the Company's resources and improve the effectiveness of its sales force. As part of this effort, Pernix has reduced its total full-time work force by approximately 23 percent. PTX: 0.59 (+0.02)
Pernix Therapeutics Announces Positive Phase IV Results of Silenor(R) vs. Zolpidem Head-to-Head Arousability Study
GlobeNewswire - Thu Jun 16, 7:00AM CDT
Data demonstrated that Pernix Therapeutics' Silenor 6 mg was superior to zolpidem 10 mg on all measures evaluated.
PTX: 0.59 (+0.02)
Pernix Therapeutics Announces the Issuance of Three New Orange Book Patents for Zohydro(R) ER with BeadTek(TM)
GlobeNewswire - Wed May 25, 7:08AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ
TX), a specialty pharmaceutical company, today announced that the United States Patent and Trademark Office has issued U.S. Patent Numbers 9,339,499 ('499 patent), 9,326,982 ('982 patent), and 9,333,201 ('201 patent), covering important safety information related to dosing patients with Zohydro ER with BeadTek. These patents, in addition to the 9,265,760 patent ('760 patent) which issued February 23, 2016, are broadly directed to a method of dosing patients with hepatic impairment with hydrocodone where no adjustment in start dose is needed for patients with mild or moderate hepatic impairment. The '760, '499, '982 and '201 patents expire July 25, 2033. PTX: 0.59 (+0.02)
Pernix Therapeutics Announces CEO Transition
GlobeNewswire - Wed May 11, 7:00AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ
TX), a specialty pharmaceutical company, today announced that Doug Drysdale, after discussions with the Company's Board of Directors, has agreed to step down as Chairman of the Board, Chief Executive Officer and President, and has resigned as a member of the Board of Directors, effective May 9, 2016. John Sedor, a current Director of Pernix Therapeutics, has been appointed Chairman of the Board and Interim Chief Executive Officer of the Company while the Board of Directors searches for a permanent CEO. The Board currently intends that Mr. Sedor will remain as Chairman of the Board when a new CEO is appointed. PTX: 0.59 (+0.02)
Pernix Therapeutics Overcomes Challenge to Treximet(R) '183 Patent
GlobeNewswire - Mon May 09, 7:00AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ
TX), a specialty pharmaceutical company, today announced that on May 6, 2016, the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) denied a petition for inter partes review (IPR) filed by Graybar Pharmaceuticals, LLC (now Gray Square Pharmaceuticals, LLC) against Pozen, Inc. This petition, which was filed on November 12, 2015, sought review of certain claims of U.S. Patent No. 7,332,183 ('183 patent), which expires 2026. The '183 patent is licensed by Pernix and is one of several FDA Orange Book listed patents covering Treximet(R), manufactured and sold by Pernix Therapeutics, (sumatriptan/naproxen sodium), a prescription medication for acute migraine attacks, with or without aura. PTX: 0.59 (+0.02), POZN: 5.94 (-0.43)
Pernix Therapeutics reports 1Q loss
Automated Insights - Thu May 05, 8:19AM CDT
MORRISTOWN, N.J. (AP) _ Pernix Therapeutics Holdings Inc. (PTX) on Thursday reported a loss of $25.9 million in its first quarter.
PTX: 0.59 (+0.02)
Pernix Therapeutics Reports First Quarter 2016 Financial Results and Business Update
GlobeNewswire - Thu May 05, 7:01AM CDT
Pernix Prescriptions Direct Achieves Increased Penetration
PTX: 0.59 (+0.02)
Pernix Therapeutics to Report First Quarter 2016 Financial Results on Thursday, May 5, 2016
GlobeNewswire - Thu Apr 28, 7:30AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ
TX), a specialty pharmaceutical company, announced today that it will release financial results for the first quarter ended March 31, 2016, before the market opens on Thursday, May 5, 2016. Doug Drysdale, Chairman and Chief Executive Officer, and Sanjay Patel, Chief Financial Officer, will host a conference call to discuss the results, as follows. PTX: 0.59 (+0.02)
Pernix Therapeutics to Present at Needham & Company's 15th Annual Healthcare Conference
GlobeNewswire - Tue Apr 05, 3:01PM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ
TX), a specialty pharmaceutical company, announced today that Doug Drysdale, Chairman and Chief Executive Officer, and Sanjay Patel, Chief Financial Officer, will present at Needham & Company's 15th Annual Healthcare Conference, as follows. PTX: 0.59 (+0.02)
Pernix Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Business Update
GlobeNewswire - Thu Mar 10, 7:00AM CST
Full Year 2015 Revenue Increases 44% Year-Over-Year to $176 Million
PTX: 0.59 (+0.02)
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launch Investigation of Pernix Therapeutics Holdings, Inc. for Possible Breaches of Fiduciary Duty
PR Newswire - Thu Jan 14, 11:15AM CST
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX) in connection with possible breaches of fiduciary duty.
PTX: 0.59 (+0.02)
Zogenix, Inc Gained 29% in 2015 -- Here's Why
Brian Feroldi, The Motley Fool - Motley Fool - Thu Jan 14, 10:59AM CST
What: 2015 was a great year to be a Zogenix shareholder. The clinical-stage biopharmaceutical company's stock soared more than 29% higher during the year, according to data from S&P Capital IQ . So what: The year was filled with...
PTX: 0.59 (+0.02), ZGNX: 9.13 (+0.05)
The Zacks Analyst Blog Highlights: Amphastar Pharmaceuticals, Mylan, Pernix Therapeutics Holdings, Eli Lilly and Novo Nordisk
Zacks Equity Research - Zacks Investment Research - Wed Nov 25, 8:30AM CST
The Zacks Analyst Blog Highlights: Amphastar Pharmaceuticals, Mylan, Pernix Therapeutics Holdings, Eli Lilly and Novo Nordisk
NVO: 56.97 (+0.43), PTX: 0.59 (+0.02), MYL: 46.79 (+0.07), LLY: 82.89 (-0.04), AMPH: 16.18 (-0.09)
Forget Allergan & Pfizer, Buy These Drug Stocks Instead
Arpita Dutt - Zacks Investment Research - Tue Nov 24, 11:09AM CST
Let's take a look at some drug stocks with an attractive Zacks Rank and positive estimate revisions.
AGN: 252.95 (-2.61), NVO: 56.97 (+0.43), PTX: 0.59 (+0.02), PFE: 36.89 (+0.22), MYL: 46.79 (+0.07), LLY: 82.89 (-0.04), AMPH: 16.18 (-0.09)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of Pernix Therapeutics Holdings, Inc. - PTX
ACCESSWIRE - Mon Nov 16, 3:30PM CST
NEW YORK, NY / ACCESSWIRE / November 16, 2015 / Levi & Korsinsky announces it has commenced an investigation of Pernix Therapeutics Holdings, Inc. (NasdaqGM: PTX) concerning possible breaches of fiduciary duty by its Board of Directors. To obtain additional information, GO TO:
PTX: 0.59 (+0.02)
Pernix Therapeutics to Present at Stifel 2015 Healthcare Conference
GlobeNewswire - Fri Nov 13, 6:00AM CST
Pernix Therapeutics Holdings, Inc. (NASDAQ
TX), a specialty pharmaceutical company, announced today that Doug Drysdale, Chairman, President and Chief Executive Officer, and Sanjay Patel, Chief Financial Officer, will present at the Stifel 2015 Healthcare Conference as follows: PTX: 0.59 (+0.02)
Pernix Therapeutics Holdings, Inc. Announces Positive Interim Results From a Phase IV Study to Assess and Compare the Effects of Silenor 6 mg and zolpidem 10 mg on Balance, Cognitive Performance, and Arousability
GlobeNewswire - Thu Nov 12, 10:15AM CST
Pernix Therapeutics Holdings, Inc. (NASDAQ
TX), a specialty pharmaceutical company, today announced positive interim results from a Phase IV Study assessing the effects of a nighttime administration of Silenor 6 mg, zolpidem 10 mg, and placebo on arousability, gait/balance, and cognitive performance in healthy volunteers. The study assessed the effects of a single dose of Silenor 6 mg compared with matching placebo and a single dose of zolpidem 10 mg compared to its matching placebo at the respective Tmax (amount of drug present at the maximum serum concentration) in normal healthy adult male volunteers (n=39). The interim results of this head-to-head comparison demonstrate that Silenor 6 mg is statistically significantly superior to zolpidem 10 mg on all measures analyzed. The results also indicate that subjects taking Silenor 6 mg did not have impairment on any of these measures and were comparable to placebo. Further, Silenor 6 mg and both placebo groups were superior to zolpidem on all measures, indicating that zolpidem subjects had significant difficulty waking up, difficulty in their ability to walk, difficulty with balance, and experienced memory impairment. PTX: 0.59 (+0.02)
